This site uses cookies to collect activity data and personalize content. By continuing to navigate this site, you agree to allow us to collect information using cookies. Learn more about how we care for your data in our privacy notice.

Accept

Pneumonia

  1. Scaling up access to oxygen is a multifaceted challenge that cuts across health areas and requires technical, financial, and political solutions. The National Scale-Up of Medical Oxygen Implementation Plan is the first policy of its kind to coordinate oxygen stakeholders and provide long-term guidance for scaling oxygen access in Uganda.
    Published: November 2019
    Type: Resource Page
  2. Pneumonia remains the deadliest infectious disease worldwide, claiming the lives of more than 800,000 children under age five every year.
    Published: November 2019
    Type: Article
  3. This spreadsheet provides publicly available information on clinical trials of respiratory syncytial virus (RSV) candidate vaccines and monoclonal antibodies intended for prevention. Sources of information for these trials are clinicaltrials.gov; who.int/ctrp; clinicaltrialsregister.eu; and anzctr.org.au, which includes clinical trial registries from 17 countries. Some information is also obtained through contact with investigators, sponsors, and funders of vaccine trials. (This spreadsheet pairs with the RSV Vaccine and mAb Snapshot, which provides a summary of the RSV vaccine and mAb candidates in development worldwide.)
    Published: October 2019
    Type: Resource Page
  4. We make vaccines affordable for low-resource countries—and so do our partners
    Published: October 2019
    Type: Article
  5. Hypoxemia, insufficient oxygen in the blood, affects millions of people each year suffering from a range of common conditions—including newborn complications, obstetric emergencies, and pneumonia. Because of the prevalence of hypoxemia, oxygen is one of the 30 high-priority lifesaving medicines for women and children included in the World Health Organization Model List of Essential Medicines. However, evidence suggests that nearly half of hospitals in low- and middle-income countries have inconsistent or no supply of oxygen, and only half have working pulse oximeters to measure the oxygen level in blood—a critical element of safe oxygen delivery. Unreliable access to safe oxygen is the result of many complex, interlocking market and health system issues. Working in close partnership with country stakeholders and industry members, PATH’s Increasing Access to Safe Oxygen and Maternal, Newborn, and Child Health (MNCH) Devices project aims to provide technical assistance and build capacity in support of oxygen delivery scale-up at the country level, with an eye toward expanding to other essential medical devices specifically for MNCH. This fact sheet provides an overview of this work.
    Published: October 2019
    Type: Resource Page
  6. This slide provides a snapshot of the respiratory syncytial virus (RSV) vaccine and monoclonal antibody (mAb) technology landscape, in the effort to track the development of RSV vaccine and mAb candidates and provide a summary of the various vaccine approaches being worked on worldwide. (This snapshot pairs with the RSV and mAb Trial Tracker, which provides publicly available information on clinical trials of RSV candidate vaccines and mAbs intended for prevention.)
    Published: August 2019
    Type: Resource Page
  7. This brief, developed by the Advancing Maternal Immunization (AMI) collaboration, describes the activities required in the near- and mid-to long-term to generate key evidence and achieve the necessary conditions for advancing respiratory syncytial virus (RSV) maternal immunization in low- and middle-income countries. It is a companion to AMI's Advancing RSV Maternal Immunization: A Gap Analysis Report, which describes the evidence, information, and policy needs of global and country decision-makers, public health program planners, and implementers who might be involved in decision-making and introducing maternal RSV vaccines.AMI is a collaboration of cross-sectoral experts convened by PATH and WHO with the purpose of advancing RSV maternal immunization.Related links:A Roadmap for Advancing RSV Maternal ImmunizationAdvancing Maternal ImmunizationAdvancing RSV Maternal Immunization: A gap analysis brief
    Published: May 2019
    Type: Resource Page
  8. PATH is on the front lines of an effort to defeat meningitis by 2030.
    Published: April 2019
    Type: Article
  9. The United States has a long history of leadership in global immunization. This educational fact sheet created by PATH and several advocacy partners highlights US government efforts in global immunization, including support for Gavi, the Vaccine Alliance; UNICEF; and the World Health Organization, as well as immunization activities carried out by the US Agency for International Development, US Department of Defense, and various agencies within the Department of Health and Human Services.
    Published: March 2019
    Type: Resource Page
  10. Drug resistance is one of the biggest threats to global health today. Vaccines can help.
    Published: January 2019
    Type: Article
Load more